Related Experiment Video

Updated: Sep 18, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications

Salem Baldi1,2, Nanbiao Long1, Shu Ma1

  • 1Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang 422000, China.

Research (Washington, D.C.)
|June 23, 2025
PubMed

Insights

Protein kinase inhibitors (PKIs) are crucial for treating diseases like cancer. Research focuses on developing more specific inhibitors to improve treatment effectiveness and reduce side effects.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Protein kinases regulate cellular signaling and are key targets for treating diseases, especially cancer.
  • Protein kinase inhibitors (PKIs) are central to modern drug development, with ongoing research for new chemical scaffolds.
  • Developing isoform-selective inhibitors is critical for precise therapeutic targeting and minimizing off-target effects.

Purpose of the Study:

  • To review recent advancements in protein kinase inhibitor (PKI) therapy.
  • To highlight the expanding therapeutic applications of PKIs beyond cancer.
  • To discuss future directions and challenges in PKI development and clinical application.

Main Methods:

  • Literature review of recent progress in protein kinase inhibitor research and development.
  • Analysis of clinical trial data and emerging therapeutic strategies.
  • Exploration of novel approaches integrating artificial intelligence and gene editing technologies.

Main Results:

  • Significant progress has been made in PKI therapy, expanding applications to inflammatory and neurodegenerative diseases.
  • The development of versatile and isoform-selective inhibitor scaffolds is essential for enhanced efficacy and reduced resistance.
  • Clinical case studies illustrate both challenges and opportunities in the evolving field of PKI treatment.

Conclusions:

  • Future PKI research must prioritize inhibitor specificity through mechanistic understanding and novel strategies.
  • Combination therapies and overcoming resistance are key to improving clinical outcomes.
  • Integrating advanced technologies like AI and CRISPR-Cas9 holds promise for next-generation PKI development.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K